Introduction
ation invites some speculation on its function during sarcomere formation and/or turnover. The impressively regular and stable organization of thick and thin filament lattices in the sarcomeres of crossstriated muscles cannot be explained by the self-assembly
Results
properties of their major constituents, actin and myosin. Instead, it is brought about by a cytoskeletal framework A novel phosphorylation site in the loop between domains My4 and My5 of myomesin whose complexity was only appreciated recently (see, e.g., review by Small et al., 1992) . The most obvious structures
In the myomesin molecule, a unique amino-terminal domain (138 residues) is followed by 12 repeat domains which involved in the regular packing of contractile filaments are the Z discs and M bands, which organize thin and thick reflect immunoglobulin cII and fibronectin type III domains respectively (Vinkemeier et al., 1993 ; Figure 1 ). Although filaments, respectively. The only component identified to date that could integrate both structures is the giant protein computer analyses of the human sequence did not indicate specific target sites for protein kinases (Vinkemeier et al., titin (also called connectin) together with its associated proteins (for a recent review, see Fürst and Gautel, 1995) .
1993), we observed that the phosphorylation-dependent mAb NE-14, which is directed against porcine neurofila-A small group of proteins specifically located in the M band is known. Apart from the ATP-regenerating enzyme ment H protein (Shaw et al., 1984) , shows cross-reactivity with purified bovine myomesin. The corresponding start with Ser479, their mass difference must reside in a carboxy-terminal end that is~60 residues shorter in the phosphorylation site locates to the~60 carboxy-terminal residues of myomesin (Obermann et al., 1995) . To search lower molecular mass fragment (Obermann et al., 1995) . If, as we assumed, the PKA phosphorylation site was identfor kinases acting on myomesin, the purified protein was incubated with three distinct protein kinases in the presence ical to the site previously identified in this region by mAb NE-14, only the higher molecular mass band should be of [ 32 P]ATP. While cAMP-dependent protein kinase A (PKA) was able to phosphorylate myomesin (Figure 2A ), phosphorylated. Figure 2A (lane 2) shows an autoradiograph of the Lys-C limited digest of bovine myomesin previprotein kinase C and casein kinase showed no reaction (data not shown). For a preliminary mapping of the phosphorylaously radioactively phosphorylated by PKA. Surprisingly both fragments are radioactively labelled. Thus, myomesin tion site, we used the limited proteolysis procedure with endoproteinase Lys-C which generates two myomesin fragshows an unexpected phosphorylation site which must lie between Ser479 and the last residue common to the two ments with M r s of 116 and 109 kDa, respectively. Since both fragments were shown by direct protein sequencing to fragments. For a more precise mapping of the PKA phosphorylation strate. This peptide is phosphorylated efficiently by PKA. Since this sequence describes a novel target site for PKA, site, we used a series of overlapping myomesin constructs amplified from the human cDNA by PCR and cloned into the kinetics of the phosphorylation reaction were compared with the kinetics of the liver pyruvate kinase peptide the modified bacterial expression vector pET described before (Obermann et al., 1996) . Corresponding recombin-LRRASLG ('kemptide'), which is an excellent substrate for PKA with a K m of 16 μM and a V max of 20.2 μmol/ ant proteins were overexpressed in Escherichia coli and purified under native conditions making use of their min/mg (Kemp et al., 1977) . Table I shows that the apparent K m value of kemptide measured under our assay carboxy-terminal (His) 6 tag to facilitate purification. Figure  2B shows the purity of the recombinant myomesin fragconditions was nearly identical to the published value. The K m of the myomesin peptide EKARLKSRPSAPWments used in the phosphorylation studies and their location with respect to the domain organization of myomesin TGQ was 532 μM. The V max was not obtained in absolute numbers, since the enzyme concentration in the commeris given in Figure 1 . Recombinant fragments were treated with PKA and ATP under standard assay conditions. SDScially available sample of PKA and in muscle extracts could not be measured. Instead, the numbers of our PAGE and corresponding autoradiographs ( Figure 2B and C) showed that myomesin My4-5 and larger fragments measurements in Table I indicate relative units. Thus the V max of the myomesin peptide phosphorylation reaction is containing these two domains (see My4-8) are phosphorylated efficiently, while My1-3, My6-8 and My9-13 are~50% of that of the kemptide reaction. Reverse phase HPLC ( Figure 3B ) shows a clear shift of the elution not substrates for PKA. Phosphoamino acid analysis of radiolabelled My4-5 and myomesin showed that PKA volume of the peptide after phosphorylation. This mobility shift indicates that under standard assay conditions the phosphorylation occurs exclusively on serine ( Figure 3A ). Closer inspection of the sequence of My4-5 in the human peptide is converted quantitatively into the phosphorylated form. Phosphorylation of the peptide was, as in My4-5, myomesin sequence (Vinkemeier et al., 1993) hinted at the rather long insertion connecting these two FN domains serine specific (data not shown).
To decide which serine in residues 474-484 is the target (see also Figure 1 ). This region of~35 residues harbours a sequence containing four basic residues, two serines and site for PKA, two constructs comprising myomesin My4-5 were made and either serine 479 or 482 was substituted two prolines, KARLKSRPSAP (residues 474-484), which is more likely to be accessible than the serines in the by alanine. The constructs were expressed in E.coli and the two recombinant myomesin fragments carrying a tightly packed β-barrels of the repeat domains. Therefore, a synthetic peptide EKARLKSRPSAPWTGQ (residues single point mutation were purified in the native state. Subsequent phosphorylation assays with PKA monitored 473-488) covering this region was tried as a PKA sub- (Kemp et al., 1977) . The lower part compares measured values for kemptide and the myomesin peptide EKARLKSRPSAPWTGQ (see Results). Phosphorylation reactions were performed as described in Materials and methods. Peptide sequences are given in column 1.
were phosphorylated as described above for purified PKA (data not shown). No difference was observed with respect to the state of differentiation of the muscle tissue from which the extract was derived. Thus the degree of phosphorylation of the myomesin My4-5 fragment was the same with extracts from rat fetal (gestation day 14), neonatal and adult rat psoas muscle (results not shown).
The ability of these extracts to phosphorylate Ser482 in the My4-5 fragment was also characterized in the presence of the PKA substrate kemptide (Kemp et al., 1977) . It resulted in a complete inhibition of the phosphorylation of the myomesin fragment. Similarly, the presence of the regulatory subunit of PKA also led to complete inhibition of the phosphorylation of the myomesin fragment (results not shown). In contrast, addition of EGTA or Ca 2ϩ / calmodulin to phosphorylation assays did not affect incorporation of radioactive phosphate into myomesin My4-5. We conclude, therefore, that myomesin phosphorylation by muscle extracts is probably the result of PKA or an enzyme closely related to PKA. fragments (m1, m2-m3, m4, m5-m6, m7, m8, m8-m9, m9, m10 and the titin kinase domain) by SDS-PAGE. A solid phase overlay assay was used to investigate the by SDS-PAGE and autoradiography ( Figure 2B and C) demonstrated that My4-5 (Ser479/Ala) is still phosphorylmyomesin-titin interaction ( Figure 5 ). Interestingly, m4 is the only titin domain which shows highly selective ated while My4-5 (Ser482/Ala) is no longer a substrate of PKA. Thus myomesin Ser482 is the phosphorylation interaction with myomesin fragments My1-8 and My4-8. Since the titin fragment m5-m6, which lies next to m4 site for PKA.
Interaction of myomesin with titin is modulated by phosphorylation of Ser482
(see domain structure in Figure 1 ) lacked myomesin binding ( Figure 5 ), we also used m5-m6 after phosphorylMyomesin is phosphorylated by skeletal muscle extracts ation by cdc2 kinase in the overlay assay. Again, no binding of myomesin fragments was observed ( Figure 5 ). A series of extracts from muscle tissues was tested for their ability to incorporate radioactive phosphate into
For a more precise mapping of the titin m4 binding site within the five domains of myomesin fragment My4-8, a myomesin. The results resembled the in vitro observations with PKA. Native myomesin purified from bovine skeletal series of constructs representing different portions of this region were made. Surprisingly, all of the myomesin muscle and the recombinant fragments listed in Figure 2 binding assay was repeated using the myomesin fragment My4-6 either directly or after PKA phosphorylation ( Figure 5B ). Interestingly, phosphorylation almost completely abolished the binding of My4-6 to titin domain m4.
The amino-terminal head domain of myomesin binds to myosin; location of the myomesin binding site on the myosin rod A previous study reported binding of myomesin to the LMM portion of myosin (Obermann et al., 1995) . For a more detailed mapping of the binding sites in both proteins, a series of recombinant myomesin fragments, and several proteolytic and recombinant derivatives of myosin were made. Figure 6A and B shows the purity of these derivatives. Again a solid phase overlay assay was used to delineate the sites of interaction. While myomesin fragments My2-3, My4-8 and My9-13 lacked binding to LMM, the myomesin fragment My1-3, which contains the head domain, showed a concentration-dependent binding to LMM ( Figure 6C ). This finding suggests that the unique amino-terminal head portion of the myomesin molecule bears the myosin binding site. The location of this binding site within the myomesin molecule is also indicated in the schematic representation given in Figure 7 .
In the same way, different myosin derivatives were used to map the myomesin binding site on the rod portion of myosin with greater precision. While proteolytic myosin rod, proteolytic and recombinant LMM as well as LMM 59 and LMM 50 were recognized by the myomesin fragment My1-3, LMM 50-75 and LMM 30 failed to bind myomesin My1-3 ( Figure 6C ). We conclude, therefore, that the myosin binding site on the myosin heavy chain is confined to the 169 amino acids between residues 1506 and 1674 located in the central part of LMM (numbers refer to the amino acid sequence of rabbit fast skeletal muscle myosin heavy chain; see Maeda et al., 1987) .
Discussion
As a ubiquitous protein of vertebrate sarcomeric M bands, binding sites in detail and to search for possible regulatory mechanisms.
Our recent biochemical characterization of myomesin fragments comprising only two FN domains lost the ability to interact with the titin domain m4 ( Figure 5 ; for domain purified from bovine skeletal muscle revealed phosphorylation present within the carboxy-terminal~60 residues of structure see Figure 1 ). In contrast, myomesin fragment My4-6, which covers the first three FN domains, retained the polypeptide (Obermann et al., 1995) . In an effort to search for the corresponding protein kinase, we now found binding to titin ( Figure 5) . The results were the same whether titin domains were spotted onto nitrocellulose a second, novel phosphorylation site. The combination of several approaches clearly established that Ser482 is the and overlayed with myomesin fragments, or the reverse order was used. This demonstrates the selectivity and only residue that is phosphorylated specifically in vitro by PKA (Figures 2 and 3 ). This serine lies in the region specificity of the solid phase overlay assay used.
Since myomesin fragment My4-6 contains the PKA connecting myomesin domains My4 and My5 (Figure 1 ) and is situated in the sequence KARLKSRPS*AP (residues phosphorylation site identified above, it was particularly interesting to see whether phosphorylation of Ser482 474-484; Vinkemeier et al., 1993) . While it is more difficult to envisage that a particular sequence located would influence the binding to titin m4. Therefore, the 2 μg per domain of titin fragments m1, m2-m3, m4, m5-m6, m5-m6(P i ), m7, m8, m8-m9, m9, m10 and titin kinase were spotted on nitrocellulose sheets and incubated with increasing concentrations (1 ϭ 0.2 μM, 2 ϭ 0.6 μM, 3 ϭ 1.8 μM) of myomesin fragments My1-5 (b), My1-8 (c), My4-8 (d), My4-5 (e), My4-6 (f), My5-6 (g), My7-8 (h) and My9-13 (i). (a) Control without myomesin in the incubation solution. Binding of recombinant myomesin fragments carrying the T7 tag was detected by T7 tag-specific antibody (for details see Materials and methods). Only My1-8, My4-8 and My4-6 bind to titin (for domain structures of myomesin and titin see Figure 1 ). This binding of myomesin to titin is restricted to titin m4. In (B), it is shown that the binding affinity of myomesin My4-6 for titin m4 is reduced strongly by phosphorylation of myomesin at Ser482. Titin m4 (0.2 μg) was spotted onto nitrocellulose sheets and overlayed with increasing concentrations (1 ϭ 0.2 μM, 2 ϭ 0.6 μM) of myomesin or with the phosphorylated species My4-6(P i ) (c) respectively. (a) Control without myomesin fragment in the incubation solution. Phosphorylation of myomesin My4-6 by PKA strongly reduces its binding affinity for titin m4.
within any of the densely packed Ig or FN repeat domains whether PKA phosphorylation of myomesin temporarily suppresses myomesin interactions during the early stages of myomesin would be a likely kinase target site, most of the basic residues in the loop sequence can be expected of myofibrillogenesis in vivo. In this context, the localization of a titin binding site to be exposed to the surrounding medium and therefore to be a part of a kinase site. This particular site in in the myomesin molecule established in this study is particularly interesting. Only fragments containing at least myomesin also describes a novel target sequence for PKA whose preferred targets show two basic residues separated the three FN domains My4-6 exhibited binding to the titin Ig domain m4 ( Figure 5 ). Single domains or pairs of by one residue from a serine or threonine (Pearson and Kemp, 1991) . In the myomesin sequence, four lysine/ neighbouring domains from My4-5 were not reactive in the solid phase overlay assay. This observation seems to arginine residues provide a basic environment aminoterminal to the phosphorylatable serine. Correspondingly, resemble the situation found in the interaction between titin and cardiac C-protein, where also a construct consisting of we find that a synthetic peptide spanning residues 473-488 is phosphorylated quantitatively by PKA under standard at least three C-protein domains was identified as the minimal requirement for titin binding (Freiburg and Gautel, conditions. The apparent K m and V max values of this reaction (see Table I ) indicate that myomesin is indeed 1996). It appears that a larger number of weak but cooperative interactions is necessary to establish the stable capable of serving as a PKA target comparable with other substrates (Pearson and Kemp, 1991) . When these values complexes of titin with its various associated proteins that can be observed in vivo. It is probably essential for the are compared, one has to take into account that most of the substrates characterized so far are soluble proteins. ordered sequence of events during sarcomeric contractionrelaxation cycles that stable connections between contractWhile for these proteins low K m values are essential to enable efficient phosphorylation in the cytosol, the high ile and cytoskeletal elements are retained. Most intriguing in this context is the finding that phosphorylation of a single local concentration of myomesin in the M band may allow for higher K m values.
serine residue (Ser482) within the myomesin binding site for titin resulted in an almost complete inhibition of The possible significance of this phosphorylation site for the in vivo situation during myofibrillogenesis is binding ( Figure 5B ). Apparently the phosphorylation state of Ser482, which is located in the loop connecting myoemphasized by the observation that extracts of various muscle tissues of different developmental stages (from mesin domains My4 and My5, regulates the three-dimensional arrangement of the three titin binding domains gestation day 16 rat embryos to adult) exhibit similar kinase activities on purified myomesin or its fragment (My4-6) in a rather complex manner. The in vitro results invite some speculation on the molecular mechanisms of My4-5 which harbours Ser482. It remains to be seen region of myomesin involved in the previously detected binding of myosin (Obermann et al., 1995) . Since only constructs that contained at least myomesin domain My1 (i.e. the unique amino-terminal domain) exhibited binding (Figure 6 ), we conclude that this domain either comprises the myosin binding site per se or is an essential part of a larger binding site. Since we could not stably express the My1 domain alone, we presently cannot distinguish between these two possibilities. Finally, we were able to locate the myomesin binding site on the myosin rod to residues 1506-1674 of the myosin heavy chain ( Figure  6C ; see Results). For a schematic representation of the established binding sites along the myomesin molecule, see Figure 7A .
The binding data presented here are in good agreement with the structural model of the sarcomeric M band region proposed on the basis of immunoelectron microscopical localizations of defined epitopes of myomesin, M-protein and the carboxy-terminal 250 kDa region of titin (Obermann et al., 1996 ; adopted in Figure 7B ). The latter results have, for instance, suggested a particular arrangement of myomesin. While most of the myomesin domains seem organized parallel to the long axis of myofibrils, the amino-terminal domains My1-2 appear to bend towards the thick filament. This region, most likely My1, indeed contains a myosin binding site (see above). Likewise, the binding of myomesin domains My4-6 to titin domain m4 described above requires close proximity of these regions to allow for these interactions to occur. This proximity is given in the structural model of the M band based on immunoelectron microscopy of defined 
Materials and methods
(C) The results of binding assays. The same amounts (~1 μg) of myosin rod, proteolytic LMM, LMM 75, LMM 59, LMM 50, LMM Expression of titin M line domains and myomesin fragments 30, LMM 50-75 and ovalbumin serving as control were spotted on in E.coli nitrocellulose filters and overlaid with increasing concentrations Original λ phage isolates containing cDNAs coding for the M band (1 ϭ 0.1 μM, 2 ϭ 0.5 μM, 3 ϭ 2.5 μM) of myomesin fragments portion of human cardiac titin (Gautel et al., 1993) were used as My1-3 (b), My2-3 (c), My4-8 (c) and My9-13 (e). (a) Control templates for PCR amplification (Saiki et al., 1985) of domains (see without protein. Binding of myomesin fragments carrying the carboxybelow). PCR products were cloned into a modified pET23a vector terminal EEF tag was detected with monoclonal antibody YL1/2, (Novagen, Heidelberg, Germany), providing the resulting proteins with which specifically recognizes this tag. Note the specific binding of an EEF tag at their carboxy-termini. Since this tag is recognized by mAb myomesin fragment My1-3 to all myosin fragments which contain at YL1/2 (Wehland et al., 1984) , expression in E.coli BL21(DE3)pLysS least the central portion of LMM (myosin heavy chain residues 1506-was monitored by immunoblot analysis. Purification of the soluble 1674; Figure 1 ). Since myomesin fragment My2-3 lacks the myosin recombinant proteins on Ni-NTA-agarose columns due to their oligohistibinding of My1-3, the myosin binding site of myomesin locates to the dine tag followed standard protocols (Qiagen, Hilden, Germany). amino-terminal head domain.
Myomesin sequences were amplified by PCR (Saiki et al., 1985) using the original λ phage isolates as templates (Vinkemeier et al., 1993) . PCR products were cloned into pET-23a derivatives. This provided the recombinant protein fragments with a carboxy-terminally located sarcomere formation, regeneration and turnover. In all His 6 sequence and with either an amino-terminally located T7 tag or a cases, local signals for either the formation or the breakcarboxy-terminal EEF tag. After growth (LB medium supplemented with 2% glucose, 100 mg/l ampicillin and 34 mg/l chloramphenicol) and down of certain complexes are needed. These could be induction of E.coli BL21(DE3) LysS cells (Studier et al., 1990) at provided by the phosphorylation/dephosphorylation of OD 600 ϭ 1 with 0.1 mM IPTG at 25°C for 3 h, the cells were harvested myomesin which in turn regulate its binding to titin. Solid phase overlay assays also delineated the molecular Fig. 7 . Diagrams summarizing established binding sites in the myomesin molecule and arrangement of titin and myomesin in the M band. In (A), myosin and titin binding sites and phosphorylation sites in the myomesin molecule are illustrated. Cross-hatched and striped boxes indicate immunoglobulin cII domains and fibronectin type III, respectively. The amino acid sequence surrounding the PKA site (Ser482) in the insert between domains My4 and My5 is shown. Brackets indicate the myomesin domains in which binding sites were located (see text). The phosphorylation site at the carboxy-terminal end arises from an unknown protein kinase (Obermann et al., 1995) . (B) A schematic representation of the arrangement of titin and myomesin molecules in the M band compatible with immunoelectron microscopical results (Obermann et al., 1996) . At the top of the diagram, a scale bar indicates distances in the M band region in nm. Shading of domains is identical to (A). For domain designations also see Figure  1 . Only two molecules of each kind are shown in order not to overburden the figure. Note the close proximity of myomesin domains My4-My6 to its binding partner, titin domain m4. For details see text. The scheme in (B) was modified from Obermann et al. (1996) . eluted with 500 mM imidazole in buffer B. After dialysis against buffer peptides were separated from [γ-32 P]ATP by the phosphocellulose binding technique described by Casnellie (1991) . Apparent K m and V max values C [50 mM Tris-HCl, pH 7.9, 1 mM EDTA, 1 mM dithiothreitol (DTT)], recombinant proteins were purified further by ion-exchange were determined by fitting the data of a double reciprocal LineweaverBurk plot to the Michaelis-Menten equation using the method of chromatography on MonoQ or MonoS FPLC columns (Pharmacia, Uppsala, Sweden). The integrity of the purified proteins was monitored least squares. by N-terminal sequencing, the reaction with specific antibodies and the EEF tag-specific antibody YL1/2 (Wehland et al., 1984) .
Phosphoamino acid analysis 32 P-Labelled protein was recovered from sample buffer by the method Mutagenesis of Wessel and Flügge (1984) , dried and hydrolysed in 6 M HCl at 110°C Serine to alanine mutations were introduced into the myomesin My4-5 for 2 h. After lyophilization, the hydrolysate was dissolved in 10 μl of fragment by PCR amplification with mismatch oligonucleotides resulting H 2 O and applied to a Polygram CEL400 Uni layer plate (Merck, in site-directed exchanges of serine to alanine codons following the Darmstadt, Germany). Electrophoretic separation of phosphoamino acids method of Ausubel et al. (1987) . Amplified fragments were subcloned was in 10% acetic acid, 1% pyridin, pH 3.5, at 800 V for 1 h. into pET-23a-derived expression vectors (see above). DNA sequencing Radioactively labelled phosphoamino acids were identified by visualizestablished the original sequence and the desired Ser-Ala exchanges.
ation of standard phosphoamino acids with ninhydrin and autoradiography. Recombinant fragments of myosin Different portions of rabbit fast skeletal muscle LMM were amplified Preparation of tissue extracts by PCR using the original cDNA of rabbit myosin heavy chain-2/10
Bovine or rat skeletal muscle, dissected into pieces, was shock-frozen (Maeda et al., 1987) as a template. Four constructs were designed, in in liquid nitrogen and stored at -80°C. Then 0.5 g of material were which the carboxy-termini were identical with the end of the original homogenized in 3 vol of ice-cold 5 mM EDTA, 15 mM 2-mercaptoethanol clone (i.e. amino acid residue 1939). The amino-termini were situated pH 7.0 and the resulting suspension clarified by centrifugation (4°C, 11 at different points along the sequence of the myosin rod portion. This 000 g, 10 min). The supernatant was applied onto a MonoQ HR 5/5 resulted in a series of 'shorter LMMs', which were designated according column (Pharmacia, Uppsala, Sweden). After washing with a buffer to their approximate molecular masses (in kDa): LMM75 (corresponding containing 50 mM Tris-HCl pH 7.9 and 1 mM DTT, protein was eluted to residues 1284-1939 of the original clone; Maeda et al., 1987) , with a linear gradient from 0 to 500 mM KCl in the same buffer. Assays LMM59 (residues 1429-1939), LMM50 (residues 1506-1939) and for kinase activity were performed as described above. LMM30 (residues 1675-1939) . In addition, a further construct, called LMM75-50, was made. It corresponds to the amino-terminal portion of Myosin binding assays LMM and represents residues 1284-1505 of the myosin heavy chain α-Chymotryptic myosin subfragments (myosin rod and LMM) and sequence. PCR products were cloned into the pET-23a expression vector recombinant LMM fragments (LMM 75, LMM 59, LMM50, LMM 50-(Novagen, Heidelberg, Germany). Recombinant LMM fragments were 75, LMM 30) were adjusted to 50 mM KCl, 5 mM Na phosphate pH 7.0 expressed in E.coli BL21(DE3)pLysS and purified by two high salt-low to allow the formation of filaments. Approximately 1 μg of each salt extraction and precipitation cycles as described (Maeda et al., 1989) . suspension was spotted onto nitrocellulose membranes (BA-85, All recombinant LMM fragments formed normal paracrystals as judged Schleicher and Schüll, Dassel, Germany). After air drying, the strips by electron microscopic inspection after negative staining (Maeda were blocked with overlay buffer (1% bovine serum albumin, 0. 2% et al., 1989) .
Tween-20, 100 mM KCl, 20 mM imidazole-HCl pH 7.0, 1 mM DTT) for 30 min. Individual strips were treated for 60 min with the respective Preparation of native proteins from bovine skeletal muscle myomesin fragments in the same buffer. After three washes with overlay Myosin rod and LMM were prepared from bovine skeletal muscle by buffer, strips were incubated for 45 min with rat monoclonal antibody proteolytic cleavage with α-chymotrypsin as described by Margossian YL1/2 (Wehland et al., 1984) , specific for the EEF tag of our recombinant and Lowey (1982) . Purification of bovine skeletal muscle myomesin and myomesin fragments. Strips were washed as described above and treated its proteolytic fragments obtained by endoproteinase Lys-C and trypsin with peroxidase-conjugated goat anti-rat antibody (Dianova) diluted have been described (Obermann et al., 1995) .
1:1000 in overlay buffer for 30 min. After a final washing cycle, antibody binding was visualized by reaction in 5 ml of 100 mM Tris-HCl pH 7.5 Phosphorylation of proteins and synthetic peptides supplemented with 100 μl of diaminobenzidine (40 mg/ml stock), 25 μl Purified myomesin, its proteolytic fragments and recombinant myomesin of NiCl 2 (80 mg/ml stock) and 1.5 μl of 30% H 2 O 2 . All steps were fragments were added at a final concentration of 0.2 μg/μl to 20 μl of performed at room temperature. assay buffer (50 mM MES pH 6.9, 100 mM KCl, 2 mM MgCl 2 ). Phosphorylation reactions were at 30°C for 30 min with 1 U of protein Titin binding assay kinase A from porcine heart (Sigma) or 1 μl of muscle extract and 1 μCi Recombinantly expressed titin fragments (0.2 μg for each domain) were of [γ-32 P]ATP (3000 Ci/mmol, Amersham). After addition of sample spotted on nitrocellulose membranes (BA-85, Schleicher and Schüll, buffer (Laemmli, 1970) and heating at 65°C for 10 min, polypeptides Dassel, Germany) pre-wetted with phosphate-buffered saline. Blocking, were analysed by 4-12 or 6-20% SDS-PAGE. Autoradiography was incubation with T7-tagged myomesin fragments and washing was as at -80°C with intensifying screens.
described for the myosin binding assays (see above). Binding to titin For the in vitro phosphorylation of titin M5-M6, recombinant titin was detected by the T7 tag-specific murine monoclonal antibody (1:1000 fragment M5-M6, containing the KSP repeats of the M band region of diluted, Novagen) followed by peroxidase-conjugated goat anti-mouse titin (Gautel et al., 1993) , was expressed solubly and purified as described antibody (1:1000 diluted, Dianova) in overlay buffer. Visualization of above. The purified protein was incubated in 100 μl of assay buffer antibody binding was as described for the myosin binding assay. (25 mM HEPES pH 7.2, 10 mM MgCl 2 , 1 mM EGTA, 1 mM DTT, 0.2 mM ATP) at 37°C for 30 min with recombinant cdc2-(New England Miscellaneous procedures Biolabs) or ERK-2 (Stratagene) SP-directed protein kinases, containing SDS-PAGE and immunoblotting were as described (Fürst et al., 1988) . final concentrations of 0.1 mg/ml of the expressed substrate protein.
Protein concentrations were obtained with the BioRad dye reagent. Maximally, 2 mol/mol of phosphate could be incorporated as judged by Synthetic peptides were obtained by Fmoc chemistry on a Pep Synthesizer parallel assays labelled with [γ-32 P]ATP and quantitation by liquid TM9050 (Millipore Co., Bedford, USA). HPLC analysis of synthetic scintillation as described by Gautel et al. (1993) . This indicates that in peptides was performed on a Vydac 218 TP54 column at 50°C using a the presence of the flanking Ig domains, not all previously described SP gradient of 0-90% acetonitrile in 0.1% trifluoroacetic acid as eluent. phosphorylation sites are fully accessible.
Synthetic peptides were phosphorylated for kinetic experiments essentially as described by Kemp et al. (1977) . Briefly, the reaction mixture
